Melanotan II: Melanocortin System Research

Melanotan II (MT-II) is a synthetic cyclic heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) developed at the University of Arizona by Hruby, Hadley, and colleagues in the early 1990s. It is a non-selective agonist of melanocortin receptors MC1R through MC5R, with activity at all five receptor subtypes.

Melanotan II was designed as a more potent and metabolically stable analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The cyclic structure, which constrains the pharmacophore sequence (His-D-Phe-Arg-Trp) into a bioactive conformation, dramatically increases receptor potency and resistance to enzymatic degradation compared to the linear alpha-MSH peptide.

With a molecular weight of approximately 1,024.2 Da, MT-II is a medium-sized peptide that is water-soluble and easily reconstituted. Its non-selective melanocortin receptor profile makes it a useful pharmacological tool for studying the melanocortin system broadly, though it also means that observed effects in biological models may reflect activation of multiple receptor subtypes simultaneously.

The melanocortin system is one of the most versatile signaling networks in mammalian physiology. Understanding it is essential for interpreting MT-II research.

**MC1R** — Expressed on melanocytes and immune cells. Primary receptor for pigmentation (melanogenesis). Activation stimulates eumelanin (dark pigment) production over pheomelanin (yellow/red pigment). Also expressed on macrophages and involved in anti-inflammatory signaling.

**MC2R** — The ACTH receptor, expressed exclusively in the adrenal cortex. Not significantly activated by MT-II due to the receptor's unique requirement for MRAP (melanocortin-2 receptor accessory protein) and preference for the full ACTH sequence.

**MC3R** — Expressed in the hypothalamus, gut, and immune cells. Involved in energy homeostasis, feeding behavior, and inflammatory regulation. Its precise role is less well defined than MC4R.

**MC4R** — Expressed predominantly in the central nervous system, particularly the hypothalamus and brainstem. Central role in appetite regulation, energy expenditure, and autonomic function. MC4R loss-of-function is the most common monogenic cause of obesity in humans. Also implicated in sexual function and erectile signaling.

**MC5R** — Widely expressed, including in sebaceous glands, adrenal glands, and immune cells. Involved in exocrine gland function and immune regulation. Less extensively characterized than other MC receptors.

MT-II activates MC1R, MC3R, MC4R, and MC5R with significant potency. This non-selectivity underlies its diverse biological effects and also represents its primary limitation as a research tool — attributing observed effects to a specific receptor subtype requires additional pharmacological controls.

MT-II has been studied across multiple biological systems reflecting the breadth of melanocortin receptor expression.

MT-II's non-selective receptor profile requires careful experimental design to attribute effects to specific receptor subtypes.

**Available selective tools:** - *SHU9119* — MC3R/MC4R antagonist. Use to block central melanocortin effects while preserving MC1R-mediated pigmentation. - *HS024* — Selective MC4R antagonist. Useful for isolating MC4R-specific contributions. - *BMS-470539* — Selective MC1R agonist. Use to study pigmentation and anti-inflammatory MC1R signaling without activating central receptors. - *Setmelanotide* — MC4R-preferring agonist. More selective than MT-II for central melanocortin studies.

**Genetic tools:** MC receptor knockout mice (MC1R-/-, MC3R-/-, MC4R-/-) are invaluable for establishing receptor-specific contributions. Compare MT-II effects in knockout versus wild-type animals to isolate receptor-specific pathways.

**Peripheral vs. central administration:** Peripheral (subcutaneous) MT-II crosses the blood-brain barrier to activate both peripheral MC1R (melanocytes) and central MC3R/MC4R (hypothalamus). ICV administration restricts effects to central MC receptors. Route of administration is a critical variable for attributing effects to peripheral versus central melanocortin signaling.

MT-II is straightforward to handle in the laboratory:

**Reconstitution:** Dissolve in bacteriostatic water or sterile saline. MT-II is highly soluble (>10 mg/mL in water) and reconstitutes immediately.

**In-vitro concentrations:** For melanogenesis assays in B16 melanoma cells or primary melanocytes, use 0.01-10 micromolar. For MC receptor activation assays (cAMP production, FRET-based reporters), use 0.001-10 micromolar across a full dose-response curve to characterize potency at each receptor subtype.

**In-vivo concentrations:** For pigmentation studies, subcutaneous administration at 0.5-1 mg/kg/day in rodents for 7-14 days. For appetite studies, ICV injection of 0.1-1 nmol produces acute anorexigenic effects. For peripheral appetite studies, subcutaneous 1-3 mg/kg.

**Stability:** MT-II is exceptionally stable due to its cyclic structure. Lyophilized material is stable at -20°C for up to 24 months. Reconstituted solutions are stable at 2-8°C for up to 30 days. Protect from light to prevent tryptophan photo-oxidation, though the cyclic constraint provides substantial protection.

*All materials are for research use only.*